C07K 16/2806
Against cd2
Official title: {against CD2}
C07K16/2806 (Against cd2) appears on 130 US grants and 231 published applications in this corpus.
Search patents in C07K- Granted patents
- 130
- Published applications
- 231
- Assignees
- 114
- Inventors
- 380
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 2 |
| 2002 | 6 | 10 |
| 2003 | 3 | 16 |
| 2004 | 4 | 7 |
| 2005 | 6 | 4 |
| 2006 | 1 | 9 |
| 2007 | 3 | 3 |
| 2008 | 3 | 10 |
| 2009 | 5 | 6 |
| 2010 | 2 | 6 |
| 2011 | 2 | 5 |
| 2012 | 2 | 6 |
| 2013 | 7 | 3 |
| 2014 | 3 | 6 |
| 2015 | 2 | 4 |
| 2016 | 9 | 16 |
| 2017 | 0 | 10 |
| 2018 | 4 | 5 |
| 2019 | 8 | 7 |
| 2020 | 4 | 14 |
| 2021 | 5 | 17 |
| 2022 | 6 | 10 |
| 2023 | 3 | 12 |
| 2024 | 7 | 23 |
| 2025 | 3 | 12 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- Method of treating an immune-related disorder or disease associated with an organ or tissue transplant with a combination of an anti-CD2 antibody and a CTLA-4 co-stimulation blockade23 Jun 2026US 12,661,399 B2Zelarion Malta Limited
- Trispecific binding molecules against BCMA and uses thereof12 May 2026US 12,624,118 B2Novartis AG
- Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer21 Apr 2026US 12,606,621 B2Precision Biologics, Inc.
- Fratricide resistant modified immune cells and methods of using the same17 Mar 2026US 12,576,151 B2Beam Therapeutics Inc.
- Improved glycan-dependent immunotherapeutic bi-specific fusion proteins and chimeric antigen receptors24 Sep 2026US 2026/0286005 A1The Regents of the University of California
- Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer17 Sep 2026US 2026/0274947 A1Precision Biologics, Inc.
- The novel monoclonal antibodies to programmed death 1 (pd-1)17 Sep 2026US 2026/0274954 A1Cstone Pharmaceuticals (Suzhou) Co., Ltd.
- Anti-cd2 antibodies for amyotrophic lateral sclerosis20 Aug 2026US 2026/0242469 A1Zelarion Malta Limited
- Modified gamma delta t cells20 Aug 2026US 2026/0242730 A1Pointloma Biosciences, Inc.
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005